Daniel Janney, Director at Esperion Therapeutics, Inc. (ESPR), sold 350,000 shares at $44.91 ($16.0M) on 2017-03-21, disclosed to the SEC on 2017-03-23.
Open-market sale of $16.0M ESPR by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $44.91 | 121,340 | $5.4M | 34.0% |
| 2 | $45.43 | 111,307 | $5.1M | 31.5% |
| 3 | $46.60 | 59,798 | $2.8M | 17.4% |
| 4 | $47.54 | 56,855 | $2.7M | 16.9% |
| 5 | $48.19 | 700 | $34K | 0.2% |
| Total | $45.80 avg | 350,000 |
| $16.0M |
| 100% |
| Filing → |
| KRYS | SELL | 2023-06-09 | $8.3M | — | Filing → |
| KRYS | SELL | 2023-05-23 | $4.8M | — | Filing → |
| KRYS | SELL | 2023-05-11 | $1.6M | — | Filing → |